文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

P2Y12抑制剂对COVID-19危重住院患者无器官支持生存期的影响:一项随机临床试验

Effect of P2Y12 Inhibitors on Organ Support-Free Survival in Critically Ill Patients Hospitalized for COVID-19: A Randomized Clinical Trial.
PubMed 文献 · JAMA Netw Open · 2023-05-01
一句话结论在COVID-19危重患者中,P2Y12抑制剂未改善无器官支持生存天数(AOR 1.07,95%CI 0.85-1.33),未增加大出血,不支持常规使用。

这项国际、开放标签、适应性平台、1:1随机临床试验纳入需ICU级别支持的COVID-19危重患者,比较P2Y12抑制剂(首选替格瑞洛)与常规治疗14天或至出院。主要终点无器官支持天数AOR 1.07(95%CI 0.85-1.33),优势后验概率72.9%。出院存活率两组分别为74.5%和72.4%(中位AOR 1.15,95%CI 0.84-1.55),大出血发生率2.7% vs 2.8%,90天死亡率25.5% vs 27.0%(AHR 0.96,95%CI 0.76-1.23,P=.77)。结论:P2Y12抑制剂未改善无器官支持生存天数,未增加大出血,不支持常规使用。

要点

  • 在COVID-19危重患者中,P2Y12抑制剂组与常规治疗组无器官支持天数AOR 1.07(95%CI 0.85-1.33),优势后验概率72.9%。
  • 出院存活率P2Y12抑制剂组74.5% vs 常规治疗组72.4%(中位AOR 1.15,95%CI 0.84-1.55;优势后验概率80.8%)。
  • 90天死亡率P2Y12抑制剂组25.5% vs 常规治疗组27.0%(AHR 0.96,95%CI 0.76-1.23;P=.77)。
  • 大出血发生率P2Y12抑制剂组2.7% vs 常规治疗组2.8%,未增加大出血。
  • 作者结论:这些数据不支持在COVID-19危重住院患者中常规使用P2Y12抑制剂。

适用人群与场景

  • 纳入:COVID-19住院且需要ICU级别支持的危重患者。
  • 场景:ICU级别支持。

处置流程与药物剂量

  • P2Y12抑制剂组:使用P2Y12抑制剂(首选替格瑞洛)14天或至出院,以较早者为准。
  • 对照组:不接受P2Y12抑制剂(常规治疗)。

研究设计与关键结果

  • 研究类型:国际、开放标签、适应性平台、1:1随机临床试验;纳入949例参与者(中位[IQR]年龄56[46-65]岁;男性603例[63.5%]),P2Y12抑制剂组479例,常规治疗组470例。
  • 干预:P2Y12抑制剂组中替格瑞洛372例(78.8%),氯吡格雷100例(21.2%);疗程14天或至出院,以较早者为准。
  • 主要终点无器官支持天数:AOR 1.07(95%可信区间0.85-1.33);优势后验概率(定义为OR>1.0)72.9%。
  • 出院存活:P2Y12抑制剂组354例(74.5%) vs 常规治疗组339例(72.4%);中位AOR 1.15(95%可信区间0.84-1.55);优势后验概率80.8%。
  • 主要安全终点大出血(国际血栓与止血学会定义):P2Y12抑制剂组13例(2.7%) vs 常规治疗组13例(2.8%)。
  • 90天死亡率:P2Y12抑制剂组估计25.5% vs 常规治疗组27.0%;AHR 0.96(95%CI 0.76-1.23;P=.77)。

证据类型、等级与局限

  • 证据类型:随机临床试验(国际、开放标签、适应性平台、1:1随机)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论:这些数据不支持在COVID-19危重住院患者中常规使用P2Y12抑制剂。
  • P2Y12抑制剂未改善无器官支持天数,未增加大出血,未改善出院存活或90天死亡率。

指南或共识出处

  • ClinicalTrials.gov Identifier: NCT04505774

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Platelet activation is a potential therapeutic target in patients with COVID-19.

OBJECTIVE: To evaluate the effect of P2Y12 inhibition among critically ill patients hospitalized for COVID-19.

DESIGN, SETTING, AND PARTICIPANTS: This international, open-label, adaptive platform, 1:1 randomized clinical trial included critically ill (requiring intensive care-level support) patients hospitalized with COVID-19. Patients were enrolled between February 26, 2021, through June 22, 2022. Enrollment was discontinued on June 22, 2022, by the trial leadership in coordination with the study sponsor given a marked slowing of the enrollment rate of critically ill patients.

INTERVENTION: Participants were randomly assigned to receive a P2Y12 inhibitor or no P2Y12 inhibitor (usual care) for 14 days or until hospital discharge, whichever was sooner. Ticagrelor was the preferred P2Y12 inhibitor.

MAIN OUTCOMES AND MEASURES: The primary outcome was organ support-free days, evaluated on an ordinal scale that combined in-hospital death and, for participants who survived to hospital discharge, the number of days free of cardiovascular or respiratory organ support up to day 21 of the index hospitalization. The primary safety outcome was major bleeding, as defined by the International Society on Thrombosis and Hemostasis.

RESULTS: At the time of trial termination, 949 participants (median [IQR] age, 56 [46-65] years; 603 male [63.5%]) had been randomly assigned, 479 to the P2Y12 inhibitor group and 470 to usual care. In the P2Y12 inhibitor group, ticagrelor was used in 372 participants (78.8%) and clopidogrel in 100 participants (21.2%). The estimated adjusted odds ratio (AOR) for the effect of P2Y12 inhibitor on organ support-free days was 1.07 (95% credible interval, 0.85-1.33). The posterior probability of superiority (defined as an OR > 1.0) was 72.9%. Overall, 354 participants (74.5%) in the P2Y12 inhibitor group and 339 participants (72.4%) in the usual care group survived to hospital discharge (median AOR, 1.15; 95% credible interval, 0.84-1.55; posterior probability of superiority, 80.8%). Major bleeding occurred in 13 participants (2.7%) in the P2Y12 inhibitor group and 13 (2.8%) in the usual care group. The estimated mortality rate at 90 days for the P2Y12 inhibitor group was 25.5% and for the usual care group was 27.0% (adjusted hazard ratio, 0.96; 95% CI, 0.76-1.23; P = .77).

CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of critically ill participants hospitalized for COVID-19, treatment with a P2Y12 inhibitor did not improve the number of days alive and free of cardiovascular or respiratory organ support. The use of the P2Y12 inhibitor did not increase major bleeding compared with usual care. These data do not support routine use of a P2Y12 inhibitor in critically ill patients hospitalized for COVID-19.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04505774.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Berger JS, Neal MD, Kornblith LZ, et al. Effect of P2Y12 Inhibitors on Organ Support-Free Survival in Critically Ill Patients Hospitalized for COVID-19: A Randomized Clinical Trial. JAMA Netw Open. 2023. PMID: 37227729. doi:10.1001/jamanetworkopen.2023.14428

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。